7 Game-Changing Biopharma and Pharma Companies to Follow in 2025

Global pharmaceutical and biopharmaceutical industry leaders continue revolutionising medicine and creating new medicines and treatments. As we step into 2025, medical progress aims to transform lives rather than only treating illnesses. From curing deadly diseases like cancer to the latest gen of vaccines, these companies are not only making the news and helping millions of patients. In the future year, new developments in genomics, individualised medicine, and sustainable drug production will be expected to expand. 

This blog explores the top 7 pharma and biopharma companies to watch in 2025. 

Whether you're an investor, a healthcare professional, or just curious about what’s next, this list is for you. 

Pfizer

Pfizer is well-known for its innovations, such as the COVID-19 vaccine. The company takes pioneering steps in approaching health challenges ranging from cancer to rare diseases. It strengthens its impact with strategic partnerships, such as collaboration with BioNTech. 

It has developed an online platform called PfizerForAll to provide Americans with easy access to healthcare. This platform is designed to simplify dealing with health issues for those who suffer from headaches, COVID-19, or flu. It also offers same-day appointments, home delivery and vaccine scheduling and has alliances with organisations like UpScriptHealth, Alto Pharmacy, and Instacart to provide these services. Pfizer is about more than just research; it is about making discoveries which impact lives.

Roche

Roche is an innovator in healthcare, combining groundbreaking science with its strong commitment to improving lives. It transforms how diseases are diagnosed and treated and is renowned for its leadership in oncology and personalised medicine. Through strategic acquisitions and partnerships, like its collaboration with Genentech, Roche accelerates its mission to deliver cutting-edge therapies. The company is advancing medicine and making a difference worldwide with a patient-first approach.

The new information provides evidence that Roche’s Evrysdi is significantly beneficial for children with Spinal Muscular Atrophy when administered before six weeks of age. The reported patients continued reaching most of their motor developmental milestones and did not require long-term invasive ventilation. It is the only non-invasive SMA treatment, and the products are approved in over a hundred countries. 

Merck & Co.

Merck is a global leader in life-changing innovations. The company focuses on developing cancer treatments like Keytruda. Merck’s Keytruda drug is used to treat a variety of cancers. The company has the potential to address the most significant health challenges. Its strategic partnerships with Moderna for mRNA technology showcase Merck’s expansion and impact in the industry. 

Merck’s NOBIVAC® NXT Canine Flu H3N2 has been approved by the USDA (United States Department of Agriculture) as a revolutionary vaccine for canine influenza that will be produced by Merck Animal Health. This is the first vaccine employing RNA-particle technology; it provides maximum safety and efficacy with a non-adjuvanted and less volume (0.5 mL) dose.

Bristol Myers Squibb

Since its inception, Bristol Myers Squibb (BMS) has been motivated to discover, develop, and deliver innovative medicines that help people overcome serious diseases. From cutting-edge cancer therapies to treatments for autoimmune conditions, BMS is committed to transforming lives through science and innovations. It has expanded its impact in the pharmaceutical industry with strategic acquisitions like Celgene and partnerships with other biotech leaders. Pharma major Bristol Myers Squibb has embarked on a $1.8M programme to support addressing SDoH (Social Determinants of Health) in Brazil, India, Thailand and the United Kingdom. 

BMS has shown its commitment to offering healthcare facilities by funding eight charities addressing cancer and blood disorders and inadequate healthcare access. The company has made efforts towards its $150 million investment to advance health equity by 2025 to increase access to proper healthcare for people worldwide. 

Novo Nordisk

Novo Nordisk helps patients suffering from chronic conditions, including diabetes, obesity, and rare blood disorders. Renowned for its inventory of insulin and hormone therapy innovations, the company is building the way for healthier futures. Novo Nordisk is transforming people's lives worldwide by expanding its reach and impact with key acquisitions and partnerships and focusing on sustainable solutions. 

Novo Nordisk also started the Childhood Obesity Prevention Initiative to target disadvantaged urban areas across the world. In coordination with cities, academic institutions, and non-profit organisations, the initiative seeks to reinforce activities and healthy eating habits in children across six targeted cities. The study examined differences in health behaviour, BMI and well-being before and after two years of the project. It will be available in Brazil, Canada, France, Japan, the Republic of South Africa and Spain to impact 1,000 children per city.

Eli Lilly and Company

Eli Lilly is known for its inventive work in diabetes, cancer, and autoimmune diseases and is constantly innovating to tackle the most challenging health issues. With strategic acquisitions like Loxo Oncology and strong partnerships with biotech firms, Lilly is expanding its capabilities to bring life-saving treatments to more people. 

Lilly and EVA Pharma recently announced they are receiving regulatory approval to release locally manufactured insulin in Egypt. This milestone stems from the companies' collaboration to expand access to affordable insulin to one million people living with diabetes in low- to middle-income countries annually by 2030. The firm had also announced a $3 billion expansion of its recently acquired manufacturing facility in Wisconsin. The investment will benefit millions of patients worldwide, boosting the production of the company's medicines, including those for diabetes and obesity.

Gilead Sciences

Gilead Sciences is recognised for its transformative work in HIV, liver diseases, and cancer. The company is constantly pushing the boundaries of science to create innovative therapies through strategic acquisitions like Kite Pharma and partnerships with other leaders. Gilead continues to discover and advance therapies across therapeutic areas like virology, oncology and inflammatory diseases. 

Gilead also entered an exclusive option and license agreement with Tubulis to develop an antibody-drug conjugate candidate for select solid tumour targets. This collaboration combines Tubulis’ Differentiated ADC Platform Technologies with Gilead’s Oncology Research and Development Expertise. The partnership agreement has provided Gilead with an Exclusive Option to License the Resulting ADC Program for further development. 

Conclusion

As we enter 2025, the pharmaceutical and biopharma industry is ready for healthcare innovation. These leaders are at the forefront of crafting a healthier future and providing patients with unmet needs. 

The companies that aim to develop life-saving cancer treatments, manage chronic conditions, and provide novel medicines are leading the way with research, discovery, transformation, empathy, and a never-ending drive to improve the world.